Loading
A phase 2 trial of IBI363 in melanoma and non-small-cell lung cancer, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.
A Study of IBI363 in Subjects with Advanced Solid Malignancies is a phase 2 interventional study registered as NCT06281678 by Innovent Biologics (Suzhou) Co. Ltd., with 178 participants planned, started 2024-04-08 and due to reach its primary completion in 2026-03-01. Interventions recorded: IBI363. Conditions listed: Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Renal Cell Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares IBI363, Innovent Biologics, Melanoma.
Shares IBI363, Innovent Biologics, Colorectal cancer.
Shares IBI363, Innovent Biologics, Small-cell lung cancer, Non-small-cell lung cancer.
Shares IBI363, Innovent Biologics.
Shares IBI363, Innovent Biologics, Melanoma.
Shares Innovent Biologics, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Innovent Biologics, Colorectal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/